Support Inclusion Body Myositis Research at Johns Hopkins

Following a surgical procedure in 2021, I began experiencing weakness in my left leg and right hand. What was initially thought to be temporary gradually worsened, and after a year and a half, I was diagnosed with Inclusion Body Myositis (IBM)—a rare, progressive neuromuscular disease with no cure or effective treatment.

Since then, I’ve worked to better understand this condition and feel incredibly fortunate to be under the care of Dr. Lisa Christopher- Stine at the Johns Hopkins Myositis Precision Center of Excellence. IBM causes ongoing muscle weakness and atrophy, making everyday tasks increasingly difficult.

That’s why your support matters. All funds raised through this page will directly support research at the Johns Hopkins Myositis Center, helping advance critical studies aimed at slowing disease progression and, ultimately, finding a cure. For gift matching, kindly direct donations to EIN: 52-0595110 and note the Myositis Center. If you would like to see if your employer matches your charitable contribution or need additional information on Matching Gifts, please visit this page for more. 

Your donation supports the groundbreaking work of Dr. Christopher-Stine and her team—and offers hope to patients like me. 

Thank you for your generosity!

Scott

About the Johns Hopkins Myositis Precision Center of Excellence

Since its founding in 2007, the Johns Hopkins Myositis Center has been a source of hope for patients living with myositis, fundamentally transforming how this rare and complex group of diseases is diagnosed, treated, and understood.  What began as a visionary, multidisciplinary effort has grown into one of the world’s leading centers for myositis care and research.  

By uniting world-class scientific discovery with deeply compassionate, patient-centered care, the Center has reshaped standards of care globally. From uncovering the immune and genetic drivers of myositis to launching a groundbreaking cellular therapy program, our work has improved – and in many cases extended – the lives of thousands of patients worldwide.  We are proud of this legacy and steadfast in our commitment to a future in which myositis is not only manageable, but curable.